ABSTRACT
Lupus erythematosus (2000): MMWR 49(RR15), 1 (1999): Ellenberg SS, Center for Biologics Evaluation & Research, FDA Statement Photosensitivity (1999): Dr. Sue Bailey, Asst Sec Defense Health Affdirs-Service Member #1 Pruritus (2000): MMWR 49(RR15), 1 (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #5 Rash (sic) (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #5, 9, 14,
25, 44 (1999): Ellenberg SS, Center for Biologics Evaluation & Research, FDA Statement Scrotal edema (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #9 Urticaria (2001): Swanson-Biearman B+, J Toxicol Clin Toxicol 39(1), 81
Hair Hair-alopecia
Other Anaphylactoid reactions
(2000): MMWR 49(RR15), 1 (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #29 Arthralgia (2000): MMWR 49(RR15), 1 (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #46 Asthenia (2000): MMWR 49(RR15), 1 Chronic fatigue syndrome (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #39 Depression (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #23 Fever (<1%) (2000): MMWR 49(RR15), 1 Gingivitis (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #32 Guillain-Barré syndrome (2000): MMWR 49(RR15), 1 (1999): Ellenberg SS, Center for Biologics Evaluation & Research, FDA Statement (2
cases) Hypersensitivity (2001): Swanson-Biearman B+, J Toxicol Clin Toxicol 39(1), 81 (1999): Ellenberg SS, Center for Biologics Evaluation & Research, FDA Statement (2
cases) (1996): Shlyakhov E+, Med Trop (Mars) 56(2), 148
(1996): Uhr JW, Physiol Rev. 46:359 (1994): Shlyakhov E+, Med Trop (Mars) 54(1):33 Injection-site burning (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #12, 27 Injection-site edema (2000): MMWR 49(RR15), 1 (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #4, 12, 32 (1999): Ellenberg SS, Center for Biologics Evaluation & Research, FDA Statement (1962): Brachman PS+, Am J Pub Health 52, 632 (up to 48 hours) (1954): Wright GG+, J Immunol 73, 387 (2.4%) Injection-site erythema (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #21, 27, 47 (1962): Brachman PS+, Am J Pub Health 52, 632 Injection-site hematoma (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Member #12 Injectlon-site hypersensitivity (2000): MMWR 49(RR15), 1 Injection-site induration (1962): Brachman PS+, Am J Pub Health 52, 632 Injection-site inflammation Injection-site nodules (sic) (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #2, 24, 28,
37, 40, 47 (1962): Brachman PS+, Am J Pub Health 52, 632 lasting up to several weeks Injection-site numbness (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #6, 13, 15,
22, 26, 31, 39, 43 Injection-site pain (2001): Swanson-Biearman B+, J Toxicol Clin Toxicol 39(1), 81 (2000): MMWR 49(RR15), 1 (1999): Bailey S MD, Asst Sec Defense Health Affairs-Service Members #1, 4, 8, 13,
18, 19, 20, 42, 45, 47, 49 (1962): Brachman PS+, Am J Pub Health 52, 632 (24-48 hours) Injection-site pruritus (1962): Brachman PS+, Am J Pub Health 52, 632 (1954): Wright GG+, J Immunol 73, 387 (2.4%) Injection-site reaction (sic) (2001): Swanson-Biearman B+, J Toxicol Clin Toxicol 39(1), 81 (30%) (2000): Hayes SC+, J R Army Med Corps 146(3), 191 (47%) (2000): MMWR 49(RR15), 1 (1999): Ellenberg SS, Center for Biologics Evaluation & Research, FDA Statement
(severe) (1963): Puziss M+, J. Bacteriol 85, 230 (1956): Darlow HM+, Lancet 2, 476 Joint pains
(1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #6, 13, 15, 22, 26, 31, 39, 43
Myalgia (2000): MMWR 49(RR15), 1 (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #1, 6, 12,
22, 40, 41 (1954): Wright GG+, J Immunol 73, 387 (0.7%) Paresthesias (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #3, 4, 11,
17, 28, 31, 34, 36, 37, 49 Systemic reactions (sic) (2000): Hayes SC+, J R Army Med Corps 146(3), 191 (47%) Tinnitus (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #1, 6, 7,
10, 11, 13, 14, 23, 24, 28, 29, 48, 49 Tremor (1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs-Service Members #1 Note: Dr. Sue Bailey, Assistant Secretary for Health Affairs, released a statement on
June 29, 1999 that ‘almost one million shots given, the anthrax immunization is proving to be one of the safest vaccination programs on record.’ The above reports occurred for ‘50 service members at one installation alone.’ Note that no number of military personnel was mentioned at this installation, nor did it give any percentages of the above reaction patterns
(Please refer to individual generic drugs for reaction patterns)
PROTEASE INHIBITORS* Generic names:
Amprenavir Trade name: Agenerase (GSK) Indinavir Trade name: Crixivan (Merck) Iopinavir (ABT-378/r) Trade name: Kaletra (Abbott) Nelfinavir Trade name: Viracept (Agouron) Ritonavir Trade name: Norvir (Abbott) Saquinavir Trade names: Invirase (Roche); Fortovase (Roche)
*Note: Protease inhibitors cause dyslipidemia which includes elevated triglycerides and cholesterol and redistribution of body fat centrally to produce the so-called ‘protease paunch,’ breast enlargement, facial atrophy, and ‘buffalo hump.’
